|Articles|November 8, 2022
- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Pharmaceutical Executive, November 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Labs and Computing Power: The Missing Link for a Revolution by 2030almost 3 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationalmost 3 years ago
A Mission of the Heartalmost 3 years ago
The New Reality for Industry Dealmaking May be Setting Inalmost 3 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?almost 3 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentalmost 3 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?almost 3 years ago
Recaps, Live & In Personabout 3 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
5
